Priam-Amedeo Houngbedji, Daria Elżbieta Nawrot, Ondřej Janďourek, Klára Konečná, Martin Novák, Pavla Paterová, Pavel Bárta, Martina Hrast Rambaher, Eva Novotná, Carlo Castellano, Matteo Mori, Fiorella Meneghetti, Monika Záhorszká, Jana Korduláková, Jan Zitko
{"title":"Investigating the Mechanism of Antimycobacterial and Antiproliferative Activity of (E)-N’-Benzylidenepyrazine-2-Carbohydrazides and their Derivatives","authors":"Priam-Amedeo Houngbedji, Daria Elżbieta Nawrot, Ondřej Janďourek, Klára Konečná, Martin Novák, Pavla Paterová, Pavel Bárta, Martina Hrast Rambaher, Eva Novotná, Carlo Castellano, Matteo Mori, Fiorella Meneghetti, Monika Záhorszká, Jana Korduláková, Jan Zitko","doi":"10.1002/cmdc.202500085","DOIUrl":null,"url":null,"abstract":"<p>A series of 33 (<i>E</i>)-<i>N</i>’-benzylidenepyrazine-2-carbohydrazides and their derivatives were synthesized and tested for biological activity. Benzylidene derivatives with 2-OH substitution on the phenyl ring (<b>18</b>: <i>R</i> = 2-OH, <b>21</b>: <i>R</i> = 2,3-diOH, and <b>22</b>: <i>R</i> = 2,4-diOH) exhibit various biological activities. Compounds <b>18</b> and <b>21</b> demonstrate antimycobacterial activity against <i>Mycobacterium tuberculosis</i> H37Ra, <i>M. tuberculosis</i> H37Rv, and <i>M. aurum,</i> with minimum inhibitory concentration values ranging from 15.625 to 62.5 μg mL<sup>−1</sup>. Compounds <b>18</b>, <b>21</b>, and <b>22</b> show mild cytotoxicity on several human cell lines (IC<sub>50</sub> ranging from 70.2 to 500 μM). Crystallographic studies confirm the (<i>E</i>)-configuration of compound <b>18</b> and a nearly planar molecular conformation. Due to their structural similarity with salicylaldehyde isonicotinoyl hydrazone (SIH), a known iron chelator, selected compounds were tested for iron-chelating properties, revealing comparable or superior activity. Mechanistic assays targeting enoyl-[acyl carrier protein] reductase (InhA), isocitrate lyase (ICL), and lipid/mycolic acid biosynthesis show no significant inhibition, suggesting a nonspecific mechanism potentially linked to iron chelation. A correlation is observed between chelating activity and cytotoxicity, while antimycobacterial activity appears to involve additional mechanisms. Pharmacokinetic studies with compound <b>18</b> reveal no specific plasma metabolites, and no significant metabolites are detected after incubation with human liver microsomes.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":"20 18","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://chemistry-europe.onlinelibrary.wiley.com/doi/epdf/10.1002/cmdc.202500085","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cmdc.202500085","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
A series of 33 (E)-N’-benzylidenepyrazine-2-carbohydrazides and their derivatives were synthesized and tested for biological activity. Benzylidene derivatives with 2-OH substitution on the phenyl ring (18: R = 2-OH, 21: R = 2,3-diOH, and 22: R = 2,4-diOH) exhibit various biological activities. Compounds 18 and 21 demonstrate antimycobacterial activity against Mycobacterium tuberculosis H37Ra, M. tuberculosis H37Rv, and M. aurum, with minimum inhibitory concentration values ranging from 15.625 to 62.5 μg mL−1. Compounds 18, 21, and 22 show mild cytotoxicity on several human cell lines (IC50 ranging from 70.2 to 500 μM). Crystallographic studies confirm the (E)-configuration of compound 18 and a nearly planar molecular conformation. Due to their structural similarity with salicylaldehyde isonicotinoyl hydrazone (SIH), a known iron chelator, selected compounds were tested for iron-chelating properties, revealing comparable or superior activity. Mechanistic assays targeting enoyl-[acyl carrier protein] reductase (InhA), isocitrate lyase (ICL), and lipid/mycolic acid biosynthesis show no significant inhibition, suggesting a nonspecific mechanism potentially linked to iron chelation. A correlation is observed between chelating activity and cytotoxicity, while antimycobacterial activity appears to involve additional mechanisms. Pharmacokinetic studies with compound 18 reveal no specific plasma metabolites, and no significant metabolites are detected after incubation with human liver microsomes.
期刊介绍:
Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies.
ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs.
Contents
ChemMedChem publishes an attractive mixture of:
Full Papers and Communications
Reviews and Minireviews
Patent Reviews
Highlights and Concepts
Book and Multimedia Reviews.